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Mutations in the Wnt signalling cascade are believed to cause aberrant proliferation of colorectal cells through T-cell factor-4 (TCF4)
and its downstream growth-modulating factors. HOXB13 is exclusively expressed in prostate and colorectum. In prostate cancers,
HOXB13 negatively regulates b-catenin/TCF4-mediated transactivation and subsequently inhibits cell growth. To study the role of
HOXB13 in colorectal tumorigenesis, we evaluated the expression of HOXB13 in 53 colorectal tumours originated from the distal
left colon to rectum with their matching normal tissues using quantitative RT–PCR analysis. Expression of HOXB13 is either lost or
diminished in 26 out of 42 valid tumours (62%), while expression of TCF4 RNA is not correlated with HOXB13 expression. TCF4
promoter analysis showed that HOXB13 does not regulate TCF4 at the transcriptional level. However, HOXB13 downregulated the
expression of TCF4 and its target gene, c-myc, at the protein level and consequently inhibited b-catenin/TCF-mediated signalling.
Functionally, forced expression of HOXB13 drove colorectal cancer (CRC) cells into growth suppression. This is the first description
of the downregulation of HOXB13 in CRC and its mechanism of action is mediated through the regulation of TCF4 protein stability.
Our results suggest that loss of HOXB13 may be an important event for colorectal cell transformation, considering that over 90% of
colorectal tumours retain mutations in the APC/b-catenin pathway.
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Colorectal cancer (CRC) is the third most common cancer in the
United States, with an estimated 146940 new cases in 2004,
including 106370 patients with colon cancer and 40570 with rectal
cancer (Jemal et al, 2004). Cancers of the proximal colon account
for 41.2% of these cases, the descending colon 4.7%, and the distal
colon and rectum 49.3% (Cheng et al, 2001). Metastatic CRC is the
second leading cause of death from cancer in North America,
largely due to the poor clinical response of tumours to
conventional chemotherapeutics.
Mutations in the Wnt signalling pathway are frequently
connected to aberrant proliferation of colon cells. Over 80% of
CRC (Bienz and Clevers, 2000; Polakis, 2000) have mutations of
adenomatous polyposis coli (APC) gene. APC complexes with Axin
and GSK3b to phosphorylate b-catenin, which will be degraded.
Mutated APC leads b-catenin to accumulate and consequently
translocate into the nucleus. In a significant fraction of sporadic
CRC lacking APC mutations, constitutively active mutations were
found in b-catenin gene and removes target residues of this kinase.
Rare mutations in Axin have also been found in colon tumours.
Taken together, all these mutations lead to the activation of
members of the T-cell factor (TCF) family transcription factor,
resulting in target gene transcription.
HOX homeobox genes regulate axial regional specification
during embryonic development and are often expressed in a
tissue-specific and stage-related manner. Hoxb13 is limitedly
expressed in the caudal extent of the spinal cord, tail bud and
urogenital sinus (Zeltser et al, 1996; Sreenath et al, 1999). In the
adult mouse, Hoxb13 is confined to the epithelial cells of the
prostate and distal colon and rectum (Zeltser et al, 1996; Sreenath
et al, 1999). Tissue-specific expression of HOXB13 is also well
reported in human (Aarnisalo et al, 1998; Edwards et al, 2005;
Hood et al, 2004; Jung et al, 2004b; Takahashi et al, 2004). The
loss-of-function Hoxb13 mouse manifests inhibition of prolifera-
tion and activation of programmed cell death in the secondary
neural tube and caudal somites (Economides et al, 2003). Recently,
we demonstrated that the forced expression of HOXB13 sup-
pressed the growth of metastatic prostate cancer cells by
disrupting b-catenin/TCF signals (Jung et al, 2004a). In particular,
HOXB13 inhibited the expression of TCF4 and subsequently
suppressed the expression of TCF-responsive genes, including c-
myc and cyclin D1. However, expression of HOXB13 was not
altered during prostate tumorigenesis. In this study, we investi-
gated the expression of HOXB13 in colorectal tumours and the
involvement of HOXB13 in the b-catenin/TCF signalling pathway.
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Reagents
pFLAG-HOXB13, pIRES-HOXB13, and Ad-GFP-HOXB13 were
described previously (Jung et al, 2004a). pIRES-TCF4RE-luc
contains four copies of the TCF4 response elements derived from
cyclin D1 promoter as also described. pBV-c-myc-luc was
generously provided by Dr Bert Vogelstein. pCMV-b-gal was from
Promega (Madison, WI, USA). To construct pTCF4-luc, a potential
promoter region encompassing B1.9kb upstream of the tran-
scription start site was predicted, acquired from human BAC clone
(clone number RP11-57H14 from the library RPCI-11.1; BACPAC
Resources, Oakland, CA, USA), and PCR-cloned into pGL-
luciferase system. Anti-FLAG M5 and anti-c-myc antibodies came
from Sigma (St Louis, MO, USA) and BD Biosciences (Palo Alto,
CA, USA), respectively. Monoclonal antibodies to TCF4 and
transcription factor IID (TFIID) came from Upstate Biotechnology
(Charlottesville, VA, USA). Anti-b-catenin was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA).
Cell cultures
Selected human CRC cells were purchased from ATCC and
propagated according to the company’s instructions. These include
HCT116, HT-29, SW480, LoVo, Caco-2, SW837, SW1463, and NCI-
H630. LNCaP human prostate cells were also cultured in RPMI
media (Invitrogen, Carlsbad, CA, USA) supplemented with 5% FBS
at 371C in an atmosphere containing 5% CO2 as described
previously (Wu et al, 1998). All cultures were fed with fresh
medium every 3–4 days.
RNA sample preparation
Cells were grown up to 80% confluency before RNA extraction.
RNA from normal rectum was purchased from two other sources
(BD Biosciences, Palo Alto, CA, USA and Stratagene, La Jolla, CA,
USA) to reduce sampling errors. RNA from LNCaP prostate cancer
cells was used for standardising the expression levels of HOXB13
and b-actin, an internal control. Surgical frozen specimens of
human colon cancer were acquired from the Indiana University
Tissue Bank. Collected tumour samples originated from rectum or
sigmoid colon included their adjacent normal colon tissues.
Samples were homogenated in PBS using Tissue Homogenizer
(Kinematica, Switzerland). Total RNAs were purified from both
cultured cells and surgical specimen using Ultraspec RNA isolation
system (Biotecx Laboratories Inc., Houston, TX, USA) as described
previously (Jung et al, 2001). Each RNA (1mg) was reverse-
transcribed using dT(15) primers and Superscript II (Invitrogen,
Carlsbad, CA, USA). No reverse transcriptase controls were run
together to identify genomic DNA contamination. RNAs were
prepared again once the contamination was found.
Quantitative RT–PCR (QRT–PCR) analysis
QRT–PCR analysis was performed using the iCycler system
(BioRad, Hercules, CA, USA) with the Quantitect SYBR Green
PCR kit (Qiagen, Valencia, CA, USA) according to the manufac-
turer’s instructions. HOXB13 primers (50-ccccactgagtttgccttctatc-30,
50-gcctcttgtccttggtgatgaac-30) are designed to amplify specifically a
coding region of 369–739. TCF4 primers were 50-tcccaccacatca-
tacgctacac-30 and 50-tcgcttgctcttctctggacag-30. Primers for b-actin
were used to show the equal loading (50-gcaccacaccttctacaatgagc-30,
50-tagcacagcctggatagcaacg-30). cDNA (50ng) were used in a final
reaction volume of 25ml. Standard curves were prepared from
serial dilutions of LNCaP cDNA. A water blank was also
incorporated in each run on 96-well optical reaction plates. PCR
cycling conditions were performed for all of the samples as follows:
10min at 951C for enzyme activation; 40 cycles for the melting
(951C, 15s): and annealing/extension (30s) steps. To assess the
specificity of each primer set, amplicons generated from the PCR
reaction were analysed by their melting point curves and
additionally run on 1% agarose gels to confirm the correct sizes
of the PCR products. Using the standard curve method generated
by amplification of 0.08–50ng of LNCaP cDNA, the resulting Ct
values were converted to picogram quantities. Then, the HOXB13
quantity was normalised by b-actin and subtracted from no
reverse transcriptase controls. This value was then averaged for
each duplicate. Each sample was prepared in duplicate and the
experiment was repeated once to increase the power analysis.
Statistical analysis was performed using GraphPad Prism
software (San Diego, CA, USA). First, the mean expression level
of HOXB13 was acquired from 38 valid normal tissues out of 42
samples analysed. Four normal samples did not show RNA
integrity as seen by b-actin amplification. Then, a 95% confidence
interval was obtained. Differences in the measured expression of
HOXB13 mRNA between normal and tumour groups were
analysed by Student’s t-test. A P-value of less than 0.05 was
considered statistically significant.
Transient transfections
Approximately 1 10
5 cells were plated in a 24-well plate 16h
before transfection. Transfections were carried out using Lipofec-
tamine 2000 (Invitrogen) with 0.1mg of reporter, 0.1mg of test
plasmid, and 20ng of pCMV-b-gal as described by the manufac-
turer’s protocol. At 6h after transfection, the cells were washed and
fed with medium containing 5% FBS. After 18h, cells were washed
with PBS, lysed with 100ml of passive lysis buffer, and assayed for
luciferase activity as relative light units using Luciferase assay
system (Promega). b-Galactosidase activity was assessed for the
normalisation and transfection efficiency. Lysates (15ml) were
incubated in 150ml of ONPG solution (1mM MgCl2, 10.8mgml
 1
o-nitrophenyl-b-D-galactopyranoside, 0.1 M sodium phosphate,
45mM b-mercaptoethanol) at 371C for 30min. Reactions were
stopped by the addition of 200mlo f1 M Na2CO3, and activity was
measured as absorbance at 420nm. Transfection experiments were
carried out in triplicate and results were reported as mean7s.d.
Western blotting assay
Cells were grown up to 80% confluence in corresponding media
containing 5% FBS. Cells were harvested, lysed with lysis buffer
(10mM HEPES (pH 7.9), 1.5mM MgCl2,1 0 m M KCl, 0.5mM DTT,
0.5mM PMSF), and incubated on ice for 10min. Nuclei from the
cell lysate were pelleted by microcentrifugation and resuspended
in nuclear extraction buffer (20mM HEPES (pH 7.9), 420mM NaCl,
1.5mM MgCl2, 0.5mM EDTA, 10mM KCl, 0.5mM DTT, 0.5mM
PMSF, 25% glycerol). Cell debris was removed by centrifugation at
41C for 5min. In all, 20mg of nuclear extracts were loaded onto
10% Bis–Tris gel (Invitrogen) and separated using the Novex
electroporation system (Invitrogen). After proteins were trans-
ferred to PVDF membrane, primary antibodies were applied,
followed by incubation with horse peroxidase-conjugated second-
ary antibodies. Blots were developed by the ECL detection system
(Pierce, Rockford, IL, USA).
Growth assays
Selected CRC cells, including HCT116, Caco-2, LoVo, and SW480,
were monitored under the fluorescence microscope after virus
infection to see the functional effect of HOXB13. Briefly, cells were
infected with either Ad-GFP or Ad-GFP-HOXB13 at a multiplicity
of infection (MOI) of 2. Every 3–4 days, fresh media were added.
An MTT in vitro proliferation assay was also performed as
described previously (Jung et al, 2004a). Briefly, cells were plated
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sonto a 96-well plate and infected with either Ad-GFP-HOXB13 or
Ad-GFP (1MOI). At days 1–7 after virus infection, cells were
stained with 25ml of 5mgml
 1 MTT solution and incubated for 2h
at 371C. The reaction was stopped by adding 100ml of extraction
buffer (50% formamide and 10% SDS, pH 4.7). After overnight
incubation at 371C, the absorbance at 570nm was measured using
a Spectra Microplate Reader (Molecular Devices, Sunnyvale, CA,
USA). Densitometric values were analysed with Student’s t-test.
RESULTS
Expression of HOXB13 in colorectal tumours
To correlate the expression of HOXB13 and colorectal tumorigen-
esis, QRT–PCR was performed in 53 colorectal tumours. In mice,
expression of Hoxb13 is restricted to rectum and distal region of
colon (Sreenath et al, 1999). Samples were tumours anatomically
originating from descending colon to rectum, consisting of nine
distal left colons, 31 sigmoid colons, and 13 rectums. Each tumour
sample was accompanied by adjacent matching normal tissues.
Total RNA was extracted from the samples followed by real-time
RT–PCR analysis using SYBR Green. b-Actin was used to
normalise samples and to quantitate RNA from epithelial cells.
We then calculated relative amounts of mRNAs by the standard
curve method in relation to b-catenin levels. Out of 53 samples, 11
samples were eliminated because of (1) the lack of RNA
preservation in repeated experiments evidenced by b-actin
expression in tumour tissues, (2) no HOXB13 expression in
normal matching tissues, leading us to suspect that origin of
tumours are anatomically HOXB13-free region, especially in distal
colon. Melt-curve analysis was also performed to eliminate
nonspecific amplification as well as the contribution from primer
dimer formation. There was no substantial difference in expression
level of HOXB13 between each anatomic region in the normal
tissues. The expression level of HOXB13 from all normal tissues
was averaged to acquire a relative expression level of HOXB13 for
each tumour. As shown in Figure 1, expression of HOXB13 mRNA
is diminished in 26 out of 42 CRC (62%). Five showed complete
loss of HOXB13 mRNA. There was no correlation between the loss
of HOXB13 and the origin of the tissues. Previously, we have
observed that HOXB13 negatively regulates the expression of TCF4
in prostate cancer cells. Therefore, we performed QRT–PCR using
TCF4-specific primers to see if HOXB13 inversely correlates to
TCF4. However, there was no inverse correlation between HOXB13
and TCF4 at the RNA level (data not shown).
HOXB13 inhibits b-catenin/TCF-mediated transactivation
In order to investigate the function of HOXB13, baseline
expression level of HOXB13 was first determined in selected
CRC cells by QRT–PCR. As shown in Figure 2A, all CRC cells did
not express significant amounts of HOXB13 compared to normal
rectum and LNCaP prostate cancer cell. Note that SW837, SW1463,
and NCI-H630 are rectum-oriented cancer cells. This result
suggests that loss of HOXB13 is also seen in all CRC cells. Next,
we investigated whether HOXB13 is involved in the regulation of
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Figure 1 Expression pattern of HOXB13 mRNA in colorectal tumours. Real-time RT–PCR was performed with RNA extracted from colorectal tumours
and matching normal tissues. Levels of HOXB13 in both normal and tumour tissues were normalised by b-actin. Relative expression of HOXB13 in normal
tissues were averaged (black bar), which was used for comparative HOXB13 expression in each tumours. Dotted line represents 95% confidence interval
for the range of HOXB13 expression in normal colorectum. *HOXB13 not detectable in tumours. Note X-axis is a log scale.
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sb-catenin-TCF-regulated transcription (CRT), which is constitu-
tively activated in most colorectal tumours. All the CRC cells used
in this study retain either truncated APC or mutation(s) in b-
catenin phosphorylation site, causing constitutive activation of
CRT (Morin et al, 1997; Shih et al, 2000). We employed artificial
promoter reporter system containing four copies of the TCF4
response elements derived from cyclin D1 promoter. Figure 2B
demonstrates that the overexpression of HOXB13 greatly inhibited
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Figure 2 HOXB13 disrupts b-catenin/TCF-mediated signals. (A) Real-
time RT–PCR was performed to show baseline levels of HOXB13 in
established colorectal tumour cell lines. Normal rectum and LNCaP
prostate cancer cells were used as references. (B) Cells were transiently
transfected with 100ng of pIRES-TCF4RE-Luc, 20ng of pCMV-b-gal, and
100ng of pFLAG-HOXB13 with or without 10nM R1881. pFLAG-CMV
was used as a counterpart of pFLAG-HOXB13. *Po0.05. (C) CV-1 cells
were transfected with either pGL-TATA-luc or pBV-myc-luc and pIRES-
HOXB13. *P¼0.02.
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Figure 3 HOXB13 suppresses expression of TCF4 at the post-
transcriptional level. (A) Cells were infected with either Ad-GFP or Ad-
GFP-HOXB13 virus (100MOI) for 48h. Nuclear proteins were separated
by gel electrophoresis followed by Western blot analysis. (B) Potential
promoter region of TCF4 was cloned into pGL-luc system (pGL-TCFp-luc)
followed by transient transfection assay. (C) Cells were transfected with
pGL-TCF4p-luc and either pFLAG or pFLAG-HOXB13. *P40.2;
**Po0.05. (D) HCT116 cells were infected with Ad-GFP or Ad-GFP-
HOXB13 (100MOI) followed by extraction of total RNA. Real-time RT–
PCR was performed for TCF4 expression and evaluated by standard curve
methods. RNA from normal rectum was used to draw the standard curve
for TCF4 and b-actin. *P¼0.32.
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sTCF4 response in all CRC cells tested. Most noticeably, HOXB13
decreased CRT activity up to 12-fold in HCT116 cells, in which
b-catenin has a deletion of Ser
45 inhibiting the downregulation of
b-catenin through phosphorylation. To avoid the possible
misinterpretation from using an artificial promoter, we studied
the effect of HOXB13 in natural c-myc promoter linked to
luciferase. c-Myc is also known to be a TCF4-responsive gene.
For higher transfection efficiency, CV-1 monkey kidney cells were
cotransfected with HOXB13 (Figure 3C). HOXB13 moderately
suppressed the promoter activity of c-myc (20%, P¼0.02).
HOXB13 suppresses the expression of TCF4 at the
translational level
HOXB13 (100MOI) was transduced into selected CRC cells via
adenoviral vector to learn how HOXB13 regulates the expression of
TCF4 and its responsive gene, c-myc. Western blot analysis
demonstrated that forced expression of HOXB13 dramatically
decreased the expression of TCF4 protein in HCT116 and SW480
cells (Figure 3A). As observed in prostate cancer cells by another
group (Chesire et al, 2002), two isoforms of TCF4 proteins (B80
and 60kDa) were detected in CRC cells. The 80kDa TCF4 isoform
is SUMO-modified and likely contribute to the majority of TCF4
activity. In our study, effect of HOXB13 was greater on the 80kDa
isoform than the 60kDa isoform. Accordingly, expression of c-myc
protein was significantly suppressed by HOXB13, especially in
HCT116 cells. While minimal suppression of b-catenin was also
observed, HOXB13 did not affect the expression of TFIID.
To see how HOXB13 is involved in the regulation of TCF4
expression, the promoter region of TCF4 was explored and tested
for the effect of HOXB13. Owing to a lack of information on the
TCF4 promoter region (Duval et al, 2000), a potential promoter
region encompassing B1.9kb upstream of the ATG site was
acquired from human BAC clone (clone number RP11-57H14 from
the library RPCI-11.1; BACPAC Resources, Oakland, CA, USA) and
PCR-cloned into pGL-luciferase system. Resulting pGL-TCF4p-luc
was transfected into HEK293, HCT116, and SW480 cells followed
by luciferase assay. The promoter region had almost 150-fold
transcriptional activity compared to pGL-TATA-luc control
(Figure 3B). To see the effect of HOXB13 on this TCF4 promoter
region, pFLAG-HOXB13 was cotransfected into the cells. However,
expression of HOXB13 did not inhibit the TCF4 promoter activity
in all cells tested (Figure 3C). Instead, HOXB13 slightly increased
the promoter activity of TCF4 in SW480 cells (Po0.05), while
HOXB13 did not affect both HEK293 and HCT116 cells (P40.05).
Consequently, overexpression of viral HOXB13 did not alter the
expression of TCF4 mRNA in HCT116 cells, as demonstrated by
QRT–PCR (Figure 3D). These results suggest that suppression of
TCF4 by HOXB13 occurs at the post-transcriptional level and may
explain why RNA expression of HOXB13 and TCF4 was not
correlated in patient tumour samples.
HOXB13 inhibits the growth of CRC cells
In order to see if HOXB13 regulates the growth of CRC cells, cells
were infected with recombinant adenovirus expressing both GFP
and HOXB13 (10MOI). Ad-CMV-GFP was used as a control virus.
Figure 4A demonstrated that HOXB13 suppressed the growth of
HCT116 cells 6 days after infection. HOXB13 also inhibited the
growth of LoVo, SW480, and Caco-2 (data not shown). The
growth-suppressive function of HOXB13 was confirmed by MTT in
vitro proliferation assay using HCT116 cells. First, cells (2 10
3)
were plated onto 96-well plates and viruses were administered as
described above (1MOI). At each indicated days, cells were lysed
and checked for OD for live cells. Figure 4B showed that HOXB13
dramatically decreased the proliferation of HCT116 cells compared
to control virus-infected cells.
These results suggest that HOXB13 functions as a growth
suppressor in CRC cells and the loss of HOXB13 may be an
important event for the CRC development. They also imply that
HOXB13’s growth suppressive function is, at least in part,
accomplished through the disruption of b-catenin/TCF signalling,
which is aberrantly activated in most of CRC.
DISCUSSION
Although HOX proteins have long been known to be important
regulators in proper embryonic development in a temporal and
spatial expression pattern, little is known about their involvement
in solid tumour formation. In addition, expression of some HOX
proteins is maintained during the adult stage without their clear
biological roles. HOXB13 is specifically, if not exclusively,
expressed in prostate and colorectum. In this study, we demon-
strated that downregulation of HOXB13 is a common event during
the colorectal tumorigenic process. Edwards et al (2005) have
recently shown that HOXB13 was markedly downregulated in
tumour compared to normal colon in their cDNA microarray
experiment despite limited number of tumour samples. We limited
patient tumour samples to those from the descending colon to
rectum since the expression of HOXB13 is known to be restricted
to the distal colon and rectum by both mouse and human studies
(Sreenath et al, 1999; Jung et al, 2004b). HOXB13 seems to function
as a growth suppressor by negatively regulating signals from the
CRT pathway, which is usually aberrantly activated in colorectal
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Figure 4 HOXB13 inhibits the proliferation of HCT116 colon cancer
cells. (A) Ad-HCT116 cells were infected with either Ad-GFP-HOXB13 or
Ad-GFP viruses (10MOI). GFP-expressing cells were monitored under the
fluorescence microscope. (B) The same study was performed as in (A). At
indicated days after virus infection (1MOI), HCT116 cells were stained
with MTT reagent and optical density at 570nm was measured.
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stumours. Overexpression of HOXB13 inhibited the expression of
TCF4 protein, not its RNA, implying that HOXB13 mediates post-
transcriptional reduction of TCF4 levels by an unknown mechan-
ism. This may explain why HOXB13 did not inversely correlate
with the expression of TCF4 in patient tumour samples in our RNA
analyses. Owing to the lack of antibodies against HOXB13,
extensive further study is needed. Nevertheless, we propose that
the loss of HOXB13 may be an additional important event for CRC
cells, conferring a growth advantage to fully utilise limited TCF4
and subsequently overexpress its downstream genes.
TCF4 is the most abundantly expressed TCF in colorectal
epithelium (Korinek et al, 1998) and directly regulates the
transcription of c-myc (He et al, 1998), cyclin D1 (Tetsu and
McCormick, 1999), and the metalloproteinase matrilysin (MMP-7)
(Brabletz et al, 1999), whose expression is thought to be the basis
for tumorigenesis. In fact, TCF4 knockout mice have complete loss
of stem cells in the small intestine (Korinek et al, 1998). c-Myc was
identified as a target of the Wnt signalling pathway, with its
expression being repressed by wild-type APC and activated by b-
catenin via inappropriate complex formation with TCF4 (He et al,
1998). It was shown that c-myc is overexpressed in early and late
stages of CRC (Sikora et al, 1987; Smith et al, 1993). In present
study, we demonstrated that HOXB13 suppressed the expression of
this powerful oncogene by possibly suppressing TCF4 expression.
In other words, loss of HOXB13 may stimulate the expression of
c-myc to help the colorectal tumour development. Compared to
HCT116 cells, SW480 cells showed much less downregulation of
c-myc protein expression in response to HOXB13 overexpression.
As described by others (Korinek et al, 1997; He et al, 1998), this is
possibly due to low-level expression of TCF4 in SW480 cells,
suggesting that other TCF/LEF isoforms are more involved in CRT
pathway.
In the prostate, we have demonstrated that HOXB13 negatively
regulates two important growth signals, CRT (Jung et al, 2004a)
and hormone-activated androgen receptor (AR)-mediated tran-
scription (Jung et al, 2004b). Depending on the status of AR,
suppression of either pathway by HOXB13 seems to inhibit the
growth of prostate cancer cells. Deregulation of CRT by HOXB13
results from the downregulation of TCF4 transcription factors,
although aberrant activation of CRT pathway is seen in only small
fractions of prostate tumours (Voeller et al, 1998; Chesire et al,
2000). In prostate cancer, however, TCF4 is regulated at the
transcription level while at the translational suppression in CRC
without known mechanism(s). It is conceivable that there may be a
difference in cell-to-cell response. Otherwise, several isoforms of
TCF4 were not differentiated by whole promoter analysis applied
in this study. Recently, there are increased evidences on
communication between AR and b-catenin/TCF signalling. In fact,
AR physically interacts with both b-catenin (Song et al, 2003) and
TCF4 (Amir et al, 2003), suggesting that AR may be deeply
involved in the function of HOXB13 as a modulator to control
these two important signalling pathways. We suppose that AR has
a protective mechanism against HOXB13-induced growth suppres-
sion by relieving HOXB13 effect on CRT or simply activating AR-
mediated signals. It is also conceivable that loss of HOXB13 will
lead tumour development and/or tumour progression to advanced
form. In fact, CRT pathway is aberrantly activated in many types of
tumours, most commonly in CRCs (Barker and Clevers, 2000;
Polakis, 2000). In addition, up to 38% of metastatic androgen-
independent prostate tumours have abnormal accumulation of
b-catenin (Chesire and Isaacs, 2002; de la Taille et al, 2003).
Owing to the nature of HOX proteins manifesting temporal and
spatial specification during the developmental stage, some HOX
proteins are destined to control the proper development of the
posterior part of the body axis. In colorectal tissues, several studies
have reported that some HOX proteins, including HOXA5,
HOXB6, HOXB8, HOXC8, and HOXC9, are expressed in normal
tissues and their deregulation is involved in colorectal tumorigen-
esis (De Vita et al, 1993; Vider et al, 2000; Wang et al, 2001).
Hoxb13 has been shown to be limitedly expressed in the caudal
extent of the spinal cord, tail bud and urogenital sinus (Zeltser
et al, 1996; Sreenath et al, 1999). Expression of Hoxb13 in adult
mouse is confined to the epithelial cells of the prostate and distal
colon and rectum (Zeltser et al, 1996; Sreenath et al, 1999). Mice
homozygous for Hoxb13 loss-of-function mutations showed
inhibition of proliferation and activation of programmed cell
death in the secondary neural tube and caudal somites (Econo-
mides et al, 2003). In addition, low HOXB13 expression is known
to involve in the skin regeneration and wound healing (Stelnicki
et al, 1998; Komuves et al, 2003; Mack et al, 2003). Accordingly,
HOXB13 expression was either downregulated or mislocalised in
several skin tumours, including melanoma, basal cell carcinoma,
and squamous cell carcinoma (Komuves et al, 2003; Hoek et al,
2004). On the other hand, Ma et al (2004) have recently reported
that HOXB13 is overexpressed in tamoxifen-resistant, estrogen
receptor-positive breast cancers (Ma et al, 2004). Ectopic
expression of HOXB13 also enhances migration and invasion in
breast cancer cells. In this study, we demonstrated that expression
of HOXB13 is frequently diminished in colorectal tumours to
confer a positive growth signal, which may be accomplished
thorough the regulation of b-catenin/TCF4 signals.
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